Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb 24;16(1):81.
doi: 10.1186/s13256-022-03290-1.

Mononeuritis multiplex as a rare and severe neurological complication of immune checkpoint inhibitors: a case report

Affiliations
Case Reports

Mononeuritis multiplex as a rare and severe neurological complication of immune checkpoint inhibitors: a case report

Safa Abdelhakim et al. J Med Case Rep. .

Abstract

Background: Mononeuritis multiplex is a rare autoimmune peripheral neuropathy that typically presents in the context of vasculitis, diabetes, infection, or as a paraneoplastic syndrome. Adverse immune-related neurological conditions have been increasingly reported with the use of immune checkpoint inhibitors against cytotoxic T-lymphocyte antigen-4 and/or the programmed cell death protein 1/programmed death ligand-1 axis. Mononeuritis multiplex has only been reported twice from treatment of cancers with immunotherapy.

Case presentation: Here we report a case of mononeuritis multiplex as a complication of immune checkpoint inhibitor therapy for melanoma. An 80-year-old non-Hispanic white female with recurrent melanoma was treated with combination ipilimumab and nivolumab and subsequently presented with progressive leg weakness, back pain, and difficulty ambulating. The diagnosis of mononeuritis multiplex was made, which was resistant to steroid pulses, chronic steroids, intravenous immunoglobulin, and rituximab. She developed progressive neurologic dysfunction and elected for hospice care. We found only two other cases reported in the literature.

Conclusions: Increased awareness, prompt recognition, and aggressive treatments are likely the best opportunity for improved outcomes in this severe side effect.

Keywords: Case report; Checkpoint inhibitors; Immune-related adverse events; Immunotherapy; Mononeuritis multiplex.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Muscle and nerve biopsy did not demonstrate evidence of vasculitis, granulomatous disease, or amyloid. Hematoxylin and eosin (H&E) stained section of skeletal muscle showing grouped atrophy (A); Gömöri trichrome highlights angulated atrophic muscle fibers (B); H&E stained section of peripheral nerve without vasculitis or significant inflammation (C); moderate endoneurial fibrosis on trichrome stain (D); intact myelin on Luxol fast blue stain (E); and preserved axons on neurofilament immunostain (F)

References

    1. Sakai K, Mochizuki H, Mochida K, Shiomi K, Amano M, Nakazato M. A case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis. Case Rep Med. 2017;2017:1093858. doi: 10.1155/2017/1093858. - DOI - PMC - PubMed
    1. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16(4):589–593. doi: 10.1093/neuonc/nou001. - DOI - PMC - PubMed
    1. Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–674. doi: 10.1016/j.csbj.2019.03.006. - DOI - PMC - PubMed
    1. Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. 2020;87(5):659–669. doi: 10.1002/ana.25708. - DOI - PubMed
    1. NCCN clinical practice guidelines in oncology. 2019. https://www.nccn.org/professionals/physician_gls/. Accessed 9 Dec 2020.

Publication types

MeSH terms